Large scale and stable production of human FVIII in the human cell line Sk-Hep-1
US8969041B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 19, 2012 |
| Grant date | Mar 3, 2015 |
| Priority date | — |
| Expiry date | Jan 19, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2531/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention refers to: 1) the method for the production of recombinant FVIII in human Sk-Hep-1 cells, comprising von Willebrand Factor (vWF) and 2) the population of human cells transduced with a vector encoding the clotting protein (FVIII). The technical object of the present patent application is intended for the cultivation of human cells in suspension and in adhesion and isolation of the culture medium containing the desired protein. The object of the invention is to provide a safer product (free of potential human viruses), that is cheaper and more stable, by means of a method that provides sufficient amounts and on industrial scale to meet the National demand.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.